Bicara Therapeutics Inc. (BCAX)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
March 2026
Bicara Therapeutics Inc. — 8-K Filing
# 🧾 What This Document Is This is a **combined 8-K filing and press release** from Bicara Therapeutics. It serves two major purposes: it officially reports their financial results for the end of 2025, and it gives a crucial update on the progress of their main drug, ficerafusp alfa. Think of it as
SEC filings
All filings →Insider trades
All insider trades →Bicara Therapeutics Inc. has no reported insider trades in the last 90 days.